Aim: This study aimed to retrospectively evaluate the efficacy and safety of ifosfamide plus paclitaxel (IT) in Japanese patients with recurrent or metastatic uterine carcinosarcoma. Methods: This study included 15 patients who received IT (ifosfamide [l.6g/m2 on days 1-3] and paclitaxel [I35mg/m2 on day 1] every 3 weeks) for recurrent or metastatic uterine carcinosarcoma. Results: The overall response rate was 38.4%, and the disease control rate was 92.3%. The median progression-free survival was 7.0 months, and the median overall survival was 9.0 months after initiation of IT therapy. The most common hematological adverse event was Grade 1-2 neutropenia. Peripheral neuropathy of Grade 1 or 2 was observed in 33.3% of cases. There was no treatment-related death. Conclusion: IT therapy showed good efficacy and tolerability in Japanese patients with recurrent or metastatic uterine carcinosarcoma.
|Number of pages||5|
|Journal||Japanese Journal of Cancer and Chemotherapy|
|Publication status||Published - Oct 2019|
- Uterine carcinosarcoma
ASJC Scopus subject areas